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Composite vector formulation for multiple siRNA
delivery as a host targeting antiviral in a cell
culture model of hepatitis C virus (HCV) infection†
E. Crouchet,‡ab R. Saad,‡abc C. Aﬀolter-Zbaraszczuk,bc J. Ogier,bc T. F. Baumert,abd
C. Schusterab and F. Meyer*bce
Hepatitis C virus (HCV) infection is a major cause of chronic liver disease and cancer worldwide. RNA
interference (RNAi)-based gene therapies have emerged recently as a promising tool to treat chronic
viral infections. Indeed, small interfering RNAs (siRNAs) provide an opportunity to target host factors
required for the viral life cycle. In this study, we evaluated a novel nanovector-based approach for siRNA
delivery in a model of chronically infected hepatic cells. We designed original composite nanoparticles
by coating the calcium phosphate core with siRNAs targeting HCV host-factors and pyridylthiourea-grafted
polyethyleneimine (pPEI). Using combinations of diﬀerent siRNAs, we observed an eﬃcient and prolonged
decrease of HCV replication. Moreover, we showed that the layer-by-layer technique of coating applied to
our nanoparticles triggers a sequential release of siRNAs acting on diﬀerent steps of the HCV life cycle.
Together, our results demonstrate the eﬃcacy of these nanoparticles for siRNA delivery and open new
perspectives for antiviral therapies.
Introduction
Chronic hepatitis C virus (HCV) infection is a major cause of
chronic hepatitis, liver cirrhosis and hepatocellular carcinoma
worldwide.1 While recently clinically licensed direct-acting
antivirals are expected to cure the large majority of infected
patients, some challenges remain for diﬃcult-to-treat patient
subgroups.2 RNA interference (RNAi)-based gene therapies
have recently emerged as a promising tool to treat chronic viral
infections.3–5 However, considering the high mutation rates
and the number of genotypes and sub-genotypes of RNA viruses
such as HCV, targeting viral sequences remains challenging.
The recent development of host targeting agents (HTAs), targeting
host factors required for viral propagation, constitutes an interesting
alternative to overcome viral mutation and resistance to treatment.6
Delivery of HTAs using the nanoparticle technology offers the
opportunity to provide an effective and innovative strategy to
widen the arsenal of antiviral therapy. From a biomaterial point
of view, RNAi-based gene therapy allows to diversify siRNA
sequences without modifying the overall chemistry of the
molecule, resulting in a highly versatile molecule targeting
different host factors with the same delivery strategy.7,8 Previous
studies on the use of siRNAs have put emphasis on several
advantages when working with such molecules. Firstly, using
cocktails of different siRNAs targeting the same gene allows
increasing the global siRNA concentration without reaching the
threshold of off-target effects.9,10 Secondly, regarding antiviral
therapy, it helps to treat multiple viral strains and sub-types.
Several studies using both in vitro and in vivo models of HCV
infection, showed that repeated treatments with two siRNAs
were better than a single siRNA treatment at minimizing the
development of escape mutants, resulting in a rapid inhibition
of viral replication.11,12 Moreover, targeting various HTAs
would be advantageous by controlling different steps of viral
infection, from viral entry to cell re-infection.6,13 Finally,
previous studies have demonstrated that, in contrast to the
siRNA technology, the overexpression of exogenously introduced
shRNA competes with that of endogenous miRNA and thus
leads to the saturation of the endogenous miRNA pathway,
resulting in serious toxicity in the mouse liver and, in some
instances, death.14 Taking into account all these data is helpful
to determine specifications for future nanovectors that could be
used for applications requiring delivery of multiple siRNAs in a
controlled manner.
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Several attempts have been made using diﬀerent approaches
of vector formulations. Studies have been performed on siRNA
modification as well as on nanovector formulation. In 2014,
Sajeesh et al. showed that tripodal RNA structures complexed
with galactose-modified polyethylene imine (PEI) could generate
eﬀective RNAi-mediated gene silencing in experimental mice
models.15 Moreover, Lee et al. demonstrated that coating
nanoparticles by alternative adsorption of polymers and siRNAs
is a successful strategy to obtain a sustained delivery of siRNAs
in vivo with a prolonged action.16 We previously developed a
composite nanoparticle model based on the same approach.
We chose to use calcium phosphate nanoparticles because they
have good biodegradability and biocompatibility in vivo. Moreover,
these nanoparticles are more stable than other vesicular vectors
such as liposomes.17 Calcium phosphate nanoparticles were,
previously, successfully coated with siRNAs and a tyrosine-
modified PEI (PEI-Tyr) by alternative adsorption. These particles
showed a high gene silencing eﬃcacy in vitro and in vivo in a
murine model of xenograft tumour.18 In the present study, we
tested similar composite nanoparticles coated with siRNAs and
pyridylthiourea-grafted polyethylenimine (pPEI) in a chronic
HCV infectionmodel. This polymer has a lower toxicity compared
to PEI-Tyr and allows a similar siRNA complexation.19,20 Using
nanoparticles coated with diﬀerent siRNAs targeting host factors
involved in the viral life cycle, we observed a great decrease of
HCV replication over 10 days. Moreover, we demonstrated that
the layer-by-layer coating technique proposed here causes a
delayed delivery of the siRNAs. Altogether, these results pave
the way to a more comprehensive use of such nanodevices in
antiviral therapy.
Results and discussion
Particle formulation and characterization
The particle formulation (CPNp(pPEI/siRNA)2.5) was performed
as previously described, using an alternate deposition of first
pPEI and then siRNAs directly after calcium phosphate particle
(CPNp) precipitation.18 1.3 mg of siRNA per layer has been used
for the coating of the nanoparticles. The concentration of pPEI
added for the coating of the particles represents a N/P ratio = 3
(N corresponding to moles of the amine groups of polymers
and P to the moles of phosphate groups of siRNAs).18 The
average hydrodynamic diameter measured by dynamic light
scattering (DLS) after coating is 83  1 nm with a positive
charge of 31  5 mV. The particle size was confirmed by
transmission electron microscopy (TEM) imaging (Fig. S1,
ESI†). Moreover, we observed that the morphology of the core
particles is the same before and after coating (Fig. S1, ESI†). In
contrast, particles generated by alternate deposition of first
siRNAs and then pPEI showed an increase of hydrodynamic
diameter up to 100 nm, reflecting severe aggregation (data not
shown). This observation points out the importance of alternate
deposition sequence. With our previous formulation, we obtained
particles with a hydrodynamic diameter of 56 nm using PEI-Tyr
as the coating agent.18 This diﬀerence could be explained by a
diﬀerent organisation of the pPEI polymer on the calcium
phosphate core. Moreover, with our new formulation (CPNp(pPEI/
siRNA)2.5), we have more PEI present on the particle surface
compared with our previous formulation (CPNp(siRNA/PEIY)2).
18
We then analysed the stability of the coated particles for
8 days by DLS measurements. We observed that the particle
diameter remains stable over time in acetate buﬀer, indicating
that coating with polymer multilayers stabilizes the particles
(Fig. S2, ESI†). Moreover, no siRNA release was detected by
electrophoretic mobility assay when the particles were incu-
bated in water or in fetal bovine serum (Fig. S3, ESI†). Since no
free siRNAs (displaying a diﬀerent migration profile compared
with complexed siRNAs) were detected, we assume that complete
encapsulation of siRNAs was obtained. This result is in accordance
with our previous data obtained using PEI-Tyr as the coating agent.
Indeed, PEI-Tyr and pPEI were synthesized using the same 25 kDa
branched PEI. Altogether, these results demonstrate that the
particles remain stable over time.
pPEI toxicity was then determined using a 3-(4,5-dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) test in human
hepatocellular carcinoma Huh7.5.1 cells. No toxicity was detected
up to 375 mM pPEI. This concentration is way above the 100 mM
pPEI classically used in our transfection experiments (Fig. S4, ESI†).
In vitro particle internalisation
Particle internalisation is of paramount importance for the
delivery and eﬃcacy of siRNAs. The overall charge of pPEI causes
non-specific interactions with the cytoplasmic membrane and
promotes non-specific internalization. Moreover, the presence of
a high tertiary amine density in PEI structure helps to trigger
particle endocytosis by the so-called ‘‘proton-sponge’’ eﬀect in
which the buﬀering capacity of PEI induces endosomal disruption
and prevents nucleic acids from lysosomal degradation. Indeed,
during PEI endocytosis, ATPase proton pumps actively translocate
protons from the cytosol into the endosomes, leading to endosome
acidification. Because of its high buﬀering capacity, PEI
becomes protonated and decreases endosome acidification.
This phenomenon results in a continuous entry of protons in
endosomes followed by a passive influx of chloride ions and water,
leading to an osmotic swelling and endosome rupture.21–23 Despite
the fact that the proton sponge effect remains the most accepted
mechanism, it is intensively debated nowadays. Recently,
Benjaminsen et al., demonstrated that PEI does not change
the endolysosome pH after cellular internalization, making
uncertain that the ‘‘proton sponge’’ effect is responsible for
PEI escape. Nevertheless this result could be explained by an
increased proton transport by V-ATPase that is able to overcome
the PEI buffering capacity and that maintains acidic conditions
in endolysosomes.24 Other authors argued that the ‘‘proton
sponge’’ effect is not the leading mechanism for PEI endosomal
escape, which could be deleterious to the cell. Another explanation
could be that PEI escapes from lysosomes through membrane
pores/holes triggered by an interaction between PEI and the
membrane combined withmembrane tension.21,24 Themechanism
of PEI escape from the endosomal/lysosomal pathway is still
elusive.
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Although there is no doubt that the particles are internalised,
their intracellular localisation and fate are unclear. To address
this question, we used TEM and confocal laser scan microscopy
(CLSM) imaging. Huh7.5.1 cells were incubated with nano-
particles for 4 h. After thorough washing to discard all non-
internalised particles, the cells were grown for an additional
24 or 48 h. TEM imaging of cells, 24 h and 48 h after particle
endocytosis, shows that the particles are evenly distributed in
the cytoplasm mainly as aggregates (Fig. 1). As expected, the
particles are neither included in vesicles nor associated with
membranes. However, the calcium phosphate core is the only
part of the particles that can be visualised by TEM. In order
to follow the presence of siRNAs, CLSM experiments were
performed on Huh7.5.1 cells after incubation with nanoparticles
containing alizarin complexone in the calcium phosphate core,
and coated with FITC labelled siRNAs. Neither core particle nor
siRNA labelling modifies the particle properties. As shown in
Fig. 2, the core of the particles (red) as well as the siRNAs (green)
are evenly distributed in the cell cytoplasm, partially co-localised,
and can be visualised for at least 7 days. This demonstrates that
the siRNAs coated on the particles are not released in the cells
at once, since fluorescence-labelled siRNAs are observed to be
co-localized with the core particles until 7 days post-treatment.
However, it is not known if siRNAs complexed with pPEI are still
available and/or released over a long period of time.
SiRNA delivery and particle toxicity
We then quantified intracellular siRNA delivery by composite
nanoparticles in Huh7.5.1 cells, by quantitative RT-PCR. Our
method allows only the detection of released siRNAs and not
siRNAs complexed with pPEI. As shown in Fig. 3, a strong
release of siRNAs was detected on the first two days after
particle internalisation, followed by a decrease of the siRNA
concentration detected. SiRNA delivery by our particles is
related to a burst release following the particle entry. When cells
are incubated with 200 ng of siRNAs no siRNAs were detected
after 4 days. However, by increasing the siRNA concentration to
400 ng about 25% of siRNAs is still detectable after 4 days (Fig. 3).
It is important to note that the remaining siRNAs detected might
be related to the non-complete destruction of siRNA released in
first instance. Our results suggest that increasing the particle
concentration could lead to a prolonged siRNA delivery in cells
and therefore a prolonged gene silencing. However, this result
must be placed in parallel with the results obtained by CLSM.
Indeed in Fig. 2, due to CLSM resolution, we can only detect
FITC-labelled siRNAs that are still complexed with pPEI on the
calcium phosphate nanoparticles. Moreover, particle aggregates
are more easily detected compared with isolated particles.
Increasing the particle concentration is so far limited by this
aspect as particle or polymer complexes aggregated into the cells
could display some toxicity.
Toxicity of such composite nanoparticles can be driven
either by pPEI itself or by the siRNAs. Since pPEI was found to
be innocuous at these concentrations (Fig. S4, ESI†), we tested
Fig. 1 TEM (transmission electron microscopy) micrograph of Huh7.5.1
cells after 24 h (upper panels) or 48 h (lower panels) incubation with
CPNp(pPEI/siRNA)2.5.
Fig. 2 Confocal laser scan microscopy (CLSM) images of Huh7.5.1 cells
after incubation with CPNp(pPEI/siRNA)2.5 showing the localisation of
calcium phosphate core particles (red) and siRNAs (green). The images
were taken at 63 magnification. Scale bars represent 5 mm.
Fig. 3 Intracellular siRNA quantification in Huh7.5.1 cells 24 h after
incubation with 400 ng of CPNp(pPEI/siLuc)2.5 (black diamonds), 200 ng
of CPNp(pPEI/siLuc)2.5 (open diamonds) and 400 ng of CPNp(pPEI/siGen1)2.5
(triangles), with siGen1 being a non targeting control siRNA. Quantification
was performed by qRT-PCR using TaqMans small RNA assays (Life
Technologies).
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in side-by-side diﬀerent siRNAs hereinafter to evaluate whether
the siRNA sequence itself could lead to cytotoxicity. To address
this question, we performed a cell viability assay on Huh7.5.1
cells incubated with diﬀerent concentrations of particles, coated
with diﬀerent siRNAs using the PrestoBlues test. The results
presented in Fig. 4 show cell viability as a function of the siRNA
quantity present on the particles for siRNAs targeting three
diﬀerent host factors. No toxicity was detected at any concentration
tested, regardless of the siRNA sequence.
Eﬀect of composite nanoparticles on chronic HCV infection in
human hepatoma cells
As a proof-of concept, we then assessed the eﬃcacy of our
particles in HCV-infected Huh7.5.1 cells.25 We used the Luc-Jc1
strain corresponding to a chimeric highly infectious HCV
genome carrying the firefly luciferase reporter gene. This strain
allows us to easily quantify viral replication, as luciferase
expression is proportional to viral replication.26 Huh7.5.1 cells
were electroporated with Luc-Jc1 RNA to obtain chronically
HCV replicating cells. We designed nanoparticles containing
4 diﬀerent siRNAs: one directly targeting viral RNA (siHCV) and
three targeting host factors involved in diﬀerent steps of the
HCV life cycle (siCD81, siRACK1 and siApoE). siHCV targets the
HCV internal ribosome entry site (IRES) sequence leading to a
direct destruction of the viral RNA.27
siCD81 targets the tetraspanin CD81, a major actor of viral
entry and therefore an important target to limit the reinfection
process.28 SiRACK1 targets the receptor for activated C kinase 1
(RACK1) that has recently been proven to play a critical role in
viral translation and replication, and therefore has been discovered
as a target for broadly acting antivirals.29 Finally, siApoE targets
apolipoprotein E (apoE), a key host factor involved in HCV entry,
assembly and release of viral particles.30–33 First, we assessed
nanoparticle efficacy in the HCV infectious model using particles
coated with a single siRNA (Fig. S5, ESI†).
Cells transfection with nanoparticles leads to a decrease in
HCV replication in a dose dependant manner at three days after
transfection regardless of the target. siHCV and siRACK1 were
the most eﬃcient, with a decrease up to 95% (1.2%) and 89%
(7.7%) of viral replication, respectively, at the highest siRNA
concentration (650 ng). Under all the conditions tested, the
highest concentrations were equivalent in eﬃcacy to a transfection
with a commercial transfection reagent (DF = Dharmafect) used as
a positive control. More interestingly, the use of pPEI alone as a
delivery platform turned out to be less eﬀective as the nano-
particles, since the presence of the calcium phosphate structure
increases the inhibition of HCV replication. Our results are in
accordance with a study published by Sokolova et al. showing that
complexation of PEI with calcium phosphate particles improves
siRNA delivery.34 As combining diﬀerent siRNAs has been shown
to increase antiviral eﬃcacy,11 we prepared nanoparticles coated
with two diﬀerent siRNAs. HTAs constitute a promising strategy to
treat HCV infection with low viral resistance to treatment.6 For
these reasons, we chose to simultaneously target two host factors
involved in diﬀerent steps of the HCV life cycle by combining
siRACK1 (viral translation/replication29) and siCD81 (viral entry
and reinfection28). We observed that the siRACK1/siCD81
association exhibited an increased eﬃcacy, especially at lower
doses, compared with siRACK1 and siCD81 alone (Fig. S5,
ESI†). For a final quantity of 130 ng of siRNA, the luciferase
signal decreases up to 67% (18.7%) for the siCD81/RACK1
mixture, instead of only 42% (8.5%) with siRACK1 alone and
10% (17.1%) with siCD81 alone.
Our previous experiments suggested that siRNAs are progressively
released in cells up to 7 days. To understand if alternate layering
changes the siRNA release sequence, we modified the particle
coating by alternative deposition of both individual siRNAs,
instead of using a mixture of siRNAs. We formulated 5 particles
coated with diﬀerent combinations of siRNAs, designed as
follows:
CPNp(pPEI/siRACK1/pPEI/siCD81/pPEI),
CPNp(pPEI/siCD81/pPEI/siRACK1/pPEI),
CPNp(pPEI/siRACK1/pPEI/siCTRL/pPEI),
CPNp(pPEI/siCTRL/pPEI/siRACK1/pPEI),
CPNp(pPEI/siRACK1 + siCD81/pPEI/siRACK1 + siCD81/pPEI).
For example, in CPNp(pPEI/siRACK1/pPEI/siCD81/pPEI) particles,
siRACK1 is close to the core particles (CPNps) and siCD81 is present
at the particle surface. Thus, siCD81 could be released early after cell
transfection, compared to siRACK1. In contrast, in CPNp(pPEI/
siCD81/pPEI/siRACK1/pPEI) particles, siRACK1 is at the particle
surface and siCD81 is close to the particle core. For a better
understanding of our results, we abbreviated the diﬀerent
formulations by indicating first the siRNA present at the particle
surface and then the second siRNA close to the particle core, e.g.
‘‘siCD81/siRACK1’’ and ‘‘siRACK1/siCD81’’ (Fig. 5).
All five types of particles were tested as described before.
HCV replicating Huh7.5.1 cells were transfected with the particles
at various concentrations. Twomain parameters were recorded at
3, 6 and 10 days after transfection: luciferase activity as a marker
of HCV replication (Fig. 5A, C and E) and RACK1 expression by
western blot analysis (Fig. 5B, D and F). As observed previously,
with a mixture of two siRNAs, a decrease of 80% (2.1%) (D3),
89% (4.6%) (D6) and 90% (3.7%) (D10) of HCV replication is
observed at the highest siRNA concentration (650 ng) (Fig. 5A).
Fig. 4 Quantification of Huh7.5.1 cell viability using a PrestoBlue test 24 h
after incubation with CPNp(pPEI/siRNA)2.5 at various concentrations. The
potential toxicity of diﬀerent siRNAs used in this study was compared:
siCD81 (grey diamond), siRACK1 (black square) and siApoE (white triangle).
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At the lowest siRNA concentration (130 ng), the sequential
coated particles present a higher inhibition eﬃciency than
the mixture-coated particles (compare Fig. 5A and E), meaning
that the sequential coating presents a functional advantage.
A decrease of RACK1 protein expression was observed by the
western blot for all types of particles. Interestingly, the silencing
is maintained up to 10 days after transfection with the two
highest concentrations. These results suggest a constant release
of siRNAs over time. However, the sequence of the coating is
important. By comparing RACK1 expression profiles and HCV
inhibition profiles, we observed a diﬀerence in RACK1 silencing
and HCV replication between siCD81/siRACK1 and siRACK1/
siCD81 particles. When siRACK1 is close to the core of the
particle (siCD81/siRACK1), we observed a decrease of RACK1
expression three days after transfection at all concentrations,
followed by a relapse from day 6, whereas when siRACK1 is at
the surface of the particles (siRACK1/siCD81), we observed a
significant decrease of RACK1 expression up to day 10. This
is particularly obvious at an intermediate concentration of
390 ng (compare siCD81/siRACK1 and siRACK1/siCD81 in
Fig. 5A and B). Such results indirectly prove that the coating
process is important to adjust siRNA delivery, and were
confirmed by another set of experiments using siRACK1 and
siCTRL (compare siCTRL/siRACK1 and siRACK1/siCTRL in
Fig. 5C and D). Moreover, we observed that siCD81/siRACK1
particles are less eﬃcient to decrease HCV infection compared
with siRACK1/siCD81 particles. All together, these results
suggest that our nanoparticle formulation allows a sequential
release of the siRNAs in cells and a sequential targeting of
two diﬀerent steps of the HCV life cycle. Moreover, we proved
that targeting first HCV translation and replication with
siRACK1 and then HCV reinfection with siCD81 in chronically
infected cells constitutes a promising strategy to inhibit HCV
propagation.
Fig. 5 Eﬀect of composite nanoparticles on HCV infection in Huh7.5.1 cells: HCV replicating cells were propagated in complete medium supplemented
with 1% DMSO to slow down cell proliferation, and transfected with various types of particles coated by alternate deposition of siCD81, siRACK1 or a
non-targeting siRNA (siCTRL). Diﬀerent combinations of siRNAs were tested: siCD81/siRACK1 or siRACK1/siCD81 (A), siCTRL/siRACK1 or siRACK1/siCTRL
(C) and a mix of siCD81 and siRACK1 (E). The particles were transfected to obtain 650, 390 or 130 ng of siRNA (final quantity). For each experiment, a
control transfection was performed using the Lipofectamine RNAiMax (Lipo) transfection protocol, purchased from Life Technologiest (Carlsbad, CA,
USA). Viral replication was assessed at 3, 6 and 10 days post-transfection by measuring the luciferase activity. The results are presented as percentage of
luciferase activity relative to non-transfected HCV replicating cells (Mock = 100%). Means  SD from three independent experiments performed in
triplicate are shown. In parallel, silencing eﬃcacy was assessed by the western blot analysis on the RACK1 protein (B, D and F). Relative quantifications
(Image J software) are expressed as a ratio RACK1/actin (fold).
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Experimental
Cell line
Human hepatoma Huh7.5.1 cells were propagated in Dulbecco’s
modified Eagle’s medium supplemented with 10% of decomple-
mented fetal bovine serum, gentamycin (50 mg mL1) and non-
essential amino acids.
RNA interference assays
Specific siRNA targeting CD81 (siCD81, L-017257-00), ApoE
(siApoE, L-006470-00), the firefly luciferase (siLuc, D-001400-01)
and non-targeting control siRNAs (siCTRL, D-001810-10-05; siGen1,
D-001206-13) were purchased from Dharmacon Inc. (Chicago, Il,
USA). The siRNA targeting HCV IRES sequence (siHCV331)
was designed by Yokota et al.27 (50-GGUCUCGUAGACCGUGCA
CTT-30). Specific siRNA targeting RACK1 (GNB2L1 silencer select,
# 4392421) was purchased from Ambion, Life technologiest
(Carlsbad, CA, USA). Target gene expression was verified by the
Western blot analysis as described previously.32
Antibodies
Mouse monoclonal anti-b-actin (ab1906) was obtained from
Abcam (Paris, France). Themousemonoclonal anti-core (MA1-080)
antibody was obtained from ThermoFisher Scientific (Waltham,
MA, USA). Mouse monoclonal anti-RACK1 (sc-17754) was obtained
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA 95060, USA).
The secondary antibody anti-mouse IgG (NXA931) coupled with
HRP was obtained from Amersham, GE Healthcare.
HCV production and infectivity
The plasmid pFK-Luc-Jc1 (Luc-Jc1) construct has been previously
described.26 Luc-Jc1 HCV RNA was obtained following T7 in vitro
transcription of the plasmid pFK-Luc-Jc1. Luc-Jc1 is a chimeric
HCV genome, which consists of J6CF structural protein segment
and JFH1 (Japanese fulminant hepatitis 1) non-structural protein
segment, and carrying the firefly-luciferase reporter gene.25,26
To obtain HCV replicating cells, Huh7.5.1 cells were electro-
porated with Luc-Jc1 viral RNA as described previously.35 Three
days post-electroporation, Luc-Jc1 replication was assessed in
cell lysates by measuring the luciferase activity.
Preparation of calcium phosphate nanoparticles
CPNps were prepared by a wet chemical process using calcium
acetate ((CH3COO)2Ca) (AR Aldrich) and sodium di-hydrogen
phosphate (NaH2PO4) (AR, Aldrich). For the precipitation process,
50 mL of NaH2PO4 solution at 2 mM, heated at 60.2 1C, were
added dropwise, at a rate of 2.5 mL min1, to 60 mL of
(CH3COO)2Ca (2 mM) and the pH was adjusted to 5.15 by adding
sodium acetate 5 mM/acetic acid, heated at 60  2 1C under
constant stirring. After precipitation the CPNp suspension was
cooled down to 4 1C for conservation until use.
siRNA and pPEI multilayer coating on nanoparticles
CPNps were coated by alternated deposition of siRNA and pPEI
leading to a polyelectrolyte multilayer (pPEI/siRNA)2,5. The pyridyl-
grafted PEI (pPEI, 30% grafting) prepared, as hydrochloride salts,
according to a described procedure from a 25 kDa branched PEI
(40,872-7, batch09529KD-466, Sigma Aldrich St Quentin, France),
was kindly provided by Dr Benoıˆt Frisch (CNRS, University of
Strasbourg, France).18 The CPNp suspension was kept at 4  2 1C
during the coating process. Before coating, the pH of the CPNp
suspension was adjusted to 5.15. Under constant stirring, 11 mL of
pPEI (10 mM N) per 1 mL of suspension was added. CPNps were
incubated for 1 h in the presence of pPEI. Then, 1.3 mg of siRNA
per mL of CPNp suspension (0.02% p/v) was added. CPNps were
incubated for 1 h in the presence of siRNA. These steps were
repeated 2 times to obtain a typical (pPEI/siRNA)2,5 coating at the
surface of the nanoparticles. After completion of the coating,
CPNp(pPEI/siRNA)2,5 were kept at 4 1C until use.
DLS and zeta potential measurements
The apparent size and surface charges of the various coated
nanoparticles were determined via dynamic light scattering
(DLS)measurements usingNanoZS apparatus (Malvern instruments,
Paris, France) with the following specifications: sampling time 90 s;
refractive index of the medium 1.3402; refractive index of particles
1.47; medium viscosity 1.145 cP and temperature 25 1C. Data were
analyzed using the multimodal number distribution software
included with the instrument. The measurements were performed
on a nanoparticle solution corresponding to a siRNA quantity of
2.6 mg per mL of nanoparticles (1.3 mg of siRNA per layer).
Electron microscopy
Huh7.5.1, seeded at 1  105 cells per cm on glass coverslips
(14mm diameter) 12 h prior to the experiment, were incubated
with CPNp(pPEI/siRNA)2,5 at a concentration of 400 ng per well.
At various times, cells were fixed in 2% PFA-2% glutaraldehyde
in 50 mM cacodylate buﬀer at pH 7.4 for 2 h. Cells were fixed in
1% osmium tetroxide in 125 mM cacodylate for 30 min.
Samples were dehydrated in solutions with gradually increasing
the concentration of ethanol (50, 70, 95, and 100% three times)
for 15 min each. Cells were included in epoxy resin (48.2% epon
812, 34% anhydride nadicmethyl, 16.4% anhydride [2-dodecenyl]
succinic, and 1.5% 2,4,6-tris [dimethylaminoethyl] phenol) for
48 h at 60 1C. After resin polymerization, in order to cut them, a
heat shock was first applied to remove glass coverslips. To obtain
sagittal sections of cells, the cutting surface was reoriented by
preparing small blocks using a circular saw (Bronwill Scientific,
USA) and sticking them on new ones. Ultra-thin cross sections
(100 nm) were obtained using an automatic ultramicrotome
(Ultracut-E Ultramicrotome, Reichert Jung, USA). The sections
were stained by 5% uranyl acetate for 20 min and 4% lead citrate.
The specimens were observed using a transmission electron
microscope EM208 (FEI Compagny, Philips, Netherlands) operating
at an accelerating voltage of 70 kV. Images were captured on
argentic SO163 Kodak films.
Confocal laser scanning microscopy
Confocal laser scanning microscopy (CLSM) observations were
carried out on a Zeiss LSM 510 microscope using a 63 (Zeiss
Achroplan) objective and with 0.4 mm z-section intervals. FITC
fluorescence was detected after excitation at l = 488 nm using a
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cut-oﬀ dichroic mirror of 488 nm and an emission band-pass
filter of 505–530 nm (green emission). Alizarin complexone
fluorescence was detected after excitation at l = 543 nm using a
dichroic mirror of 543 nm, and an emission long pass filter of
585 nm (red emission).
Nanoparticle transfection
HCV replicating cell transfection. Huh7.5.1 cells chronically
replicating HCV were propagated in complete medium
(described above). CPNps were diluted in fresh medium to
obtain 650, 520, 390, 260 and 130 ng of siRNA (final quantity)
and added to the HCV replicating cells. Cells were lysed 3 days
later and viral infection was assessed by measuring the luciferase
activity. For each experiment, control transfections were per-
formed using a mix of 12 nmol of pPEI polymer and 650 ng
of siRNA (pPEI) and by transfecting cells with the diﬀerent
siRNAs using a commercially available transfection reagent
(DF = Dharmafect, purchased from Dharmacon Inc.).
Kinetic. HCV replicating Huh7.5.1 cells were propagated in
complete medium supplemented with 1% of DMSO to decrease
cell proliferation. CPNps were diluted in medium plus DMSO to
obtain 650, 390 or 130 ng of siRNA (final quantity) and added to
the HCV replicating cells. Cells were lysed at 3, 6 or 10 days after
CPNp transfection to measure HCV replication by luciferase assay.
For each experiment, a negative control transfection was
performed using 12 nmol of pPEI polymer added in the culture
medium of Huh7.5.1 cells and a positive control transfection
was performed by transfecting siRNAs with a commercially
available transfection reagent (Lipofectamine, purchased from
Life Technologiest (Carlsbad, CA, USA)).
Cell viability assay
CPNp toxicity was assessed using PrestoBlues cell viability
reagent purchased from Life Technologiest (Carlsbad, CA,
USA), according to the manufacturer’s instructions. Briefly,
the PrestoBlues reagent was added to the cell culture medium
of transfected or control Huh7.5.1 cells. After 1 h at 37 1C,
absorbance was measured at 570 nm and 600 nm (reference
wavelengths) using a microplate reader (Mithras LB 940, Berthold
Technologies).
Statistics
Data sets were analyzed using the Mann–Whitney test. Po 0.05
and 0.01 were considered statistically significant. Significant
p values are indicated by asterisks in the individual figures: * =
p o 0.05; ** = o 0.01.
Conclusions
Our composite nanoparticles prepared by alternate deposition
of siRNA and pPEI proved to be eﬃcient in controlling HCV
replication with up to 90% reduction over 10 days. Eﬃcacy is
directly related to the type of siRNA, the intracellular pathway
targeted, and more interestingly the design of the deposition.
Here, we show that the use of calcium phosphate particles
improves the transfection eﬃcacy of pPEI and confirm the
works previously done by others using PEI. Our data pave the
way for a better understanding of PEI transfection that is still
believed to be the best candidate for synthetic transfection in
the frame of therapeutic approaches. Moreover, the results
presented here show that sequential siRNA deposition leads
to a sequential release. Thus, these types of particles could be a
useful tool for screening various pathways in the viral cycle in a
time dependant assay to decipher robust targets for viral
infection as well as cell circuits leading to cancer.
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